Alkermes vs Rhythm Pharmaceuticals

Alkermes (ALKS), health care, and Rhythm Pharmaceuticals (RYTM), health care, side by side on market value, valuation, margins, balance sheet and price change. Higher and lower are marked; neither is called better.

Rhythm Pharmaceuticals is worth $8.1B on the stock market and Alkermes $7.6B: Rhythm Pharmaceuticals is valued at 6% more. Alkermes's operating margin in its latest fiscal year was 17.2% and Rhythm Pharmaceuticals's -101%. Over the past year Alkermes's share price has moved +59.0% and Rhythm Pharmaceuticals's +6.93%.

Key facts

Alkermes market value
$7.6B
Rhythm Pharmaceuticals market value
$8.1B
Alkermes revenue
$1.5BFY to 2025-12-31
Rhythm Pharmaceuticals revenue
$189.8MFY to 2025-12-31
Superinvestors holding both
1

Market values as of .

Alkermes vs Rhythm Pharmaceuticals: every measure side by side
Measure Alkermes Rhythm Pharmaceuticals
SectorHealth CareHealth Care
Country Ireland United States
Fiscal year ends2025-12-312025-12-31
Size
Market cap$7.6Blower$8.1Bhigher
Revenue$1.5Bhigher$189.8Mlower
Earnings$241.7Mhigher-$196.5Mlower
Employees2,050higher414lower
Total assets$2.5Bhigher$480.2Mlower
Valuation
P/E——
P/S5.2lower42.7higher
P/B—92.0
Dividend yield—0.00%
Profitability
Operating margin17.2%higher-101%lower
Balance sheet
Net assets$1.8Bhigher$139.1Mlower
Total liabilities$667.7Mhigher$210.2Mlower
Total debt—$108.2M
Cash on hand$388.6Mhigher$54.3Mlower
Price change
Today-2.41%lower+8.62%higher
1 year+59.0%higher+6.93%lower

Market value, P/E, P/B, dividend yield and price changes are from live quotes (Yahoo Finance; prices may be delayed 15 minutes or more). Revenue, earnings, operating margin and the balance-sheet figures are from each company's latest annual report filed with the SEC (collected 2026-11-12); a company that reports in another currency is converted to US dollars at the exchange rate of that day. P/S sets today's market value against the latest fiscal year's revenue. “Higher” and “lower” compare the two numbers only; a higher P/E or more debt is not better. Dividend yield and P/B are shown only for companies based in the US. A dash means no figure is on file.

Loading the one-year price chart…

Which superinvestors hold them

From each tracked investor's latest 13F filing. A 13F lists long positions in US-listed shares at a quarter end, filed up to 45 days later.

Both (1)

Rhythm Pharmaceuticals only (3)

Percentages are each holding's share of that investor's reported portfolio (under "Both": Alkermes / Rhythm Pharmaceuticals). Who owns ALKS · Who owns RYTM

Further comparisons

Learn

Questions and answers

Which is bigger, Alkermes or Rhythm Pharmaceuticals?

By market value, Rhythm Pharmaceuticals is the larger: $8.1B against $7.6B for Alkermes. By revenue in its latest fiscal year, Alkermes is the larger: $1.5B against $189.8M for Rhythm Pharmaceuticals.

Which has the higher operating margin?

Alkermes: 17.2%, against -101% for Rhythm Pharmaceuticals. Operating margin is operating income as a share of revenue in the latest fiscal year.

Which superinvestors own both Alkermes and Rhythm Pharmaceuticals?

In their latest 13F filings, Julian and Felix Baker holds both.

Cite this page

Funkfolio, “Alkermes vs Rhythm Pharmaceuticals”, data as of 17 November 2026. https://funkfolio.com/compare/alks-vs-rytm

Underlying data: Yahoo Finance quotes; SEC annual reports collected 2026-11-12; 13F filings.